| 前收盘价格 | 1.83 |
| 收盘价格 | 1.86 |
| 成交量 | 189,846 |
| 平均成交量 (3个月) | 1,352,422 |
| 市值 | 113,865,352 |
| 价格/销量 (P/S) | 1.12 |
| 股市价格/股市净资产 (P/B) | 2.11 |
| 52周波幅 | |
| 利润日期 | 12 Nov 2025 |
| 营业毛利率 | -36.23% |
| 营业利益率 (TTM) | -323.11% |
| 稀释每股收益 (EPS TTM) | -0.880 |
| 季度收入增长率 (YOY) | 44.90% |
| 季度盈利增长率 (YOY) | 220.80% |
| 总债务/股东权益 (D/E MRQ) | 47.35% |
| 流动比率 (MRQ) | 3.28 |
| 营业现金流 (OCF TTM) | -69.62 M |
| 杠杆自由现金流 (LFCF TTM) | -40.45 M |
| 资产报酬率 (ROA TTM) | -26.29% |
| 股东权益报酬率 (ROE TTM) | -60.25% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | MacroGenics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
-0.1
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.13 |
|
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 3.01% |
| 机构持股比例 | 73.84% |
| 52周波幅 | ||
| 中 | 4.00 (122.22%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Barclays | 10 Mar 2026 | 4.00 (122.22%) | 购买 | 2.36 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合